Seelos Announces Issuance of a New Patent and an Additional Notice of Allowance in Japan for Intranasal Racemic Ketamine

- September 14th, 2020

Patents Further Strengthen Global Intellectual Property Portfolio in Psychiatry Seelos Therapeutics, Inc. a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today that it has received an issued patent from the Japanese Patent Office covering SLS-002 titled: ANXIOLYTIC COMPOSITION, FORMULATION AND METHOD OF USE.  The …

Patents Further Strengthen Global Intellectual Property Portfolio in Psychiatry

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today that it has received an issued patent from the Japanese Patent Office (Japanese patent number 6722453) covering SLS-002 titled: ANXIOLYTIC COMPOSITION, FORMULATION AND METHOD OF USE.  The issued claims cover a formulation and method of using SLS-002 to treat patients experiencing anxiety due to phobic disorders such as: Specific Phobia, Agoraphobia, and Social Phobia.

Additionally, Seelos has received a Notice of Allowance from the Japanese Patent Office (Japanese patent application number 2018-124196) covering SLS-002 titled: ANXIOLYTIC COMPOSITION, FORMULATION AND METHOD OF USE.  The allowed claims cover a formulation and method of using SLS-002 to prevent anxiety in patients prior to medical or dental procedures. 

Contact Information:
Anthony Marciano
Head of Corporate Communications
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Ave., 12th Fl
New York, NY 10022
(646) 293-2136
anthony.marciano@seelostx.com 
www.seelostherapeutics.com
https://twitter.com/seelostx
https://www.linkedin.com/company/seelos 

Logo – https://mma.prnewswire.com/media/1244961/Seelos_Therapeutics_Logo.jpg

SOURCE Seelos Therapeutics, Inc.

News Provided by PR Newswire via QuoteMedia

 

New FREE Report: Investing in Psychedelics

   
What’s ahead for this exciting new segment? Learn more with our exclusive psychedelics report today.
 

Leave a Reply